SciSparc granted patent for core-technology

SciSparc announced that it has been granted a patent for its core-technology, the combination of cannabinoids and n-acylethanolamines, by the Canadian Intellectual Property Office. The Patent aligns seamlessly with the Company’s proprietary technology and is designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits. This patent grant adds to the patent portfolio of the Company, thereby supporting the innovation of SciSparc’s technologies. Oz Adler, CEO of SciSparc, commented, “With this patent, we continue to strengthen our global intellectual property rights. SciSparc is a unique company in the cannabis space. We believe we are building value for our investors, as the Company continues to develop technologies for the treatment of central nervous system disorders.”